Bionano Genomics shares are trading lower after the company cut its preliminary Q3 revenue guidance.
Portfolio Pulse from Benzinga Newsdesk
Bionano Genomics shares are experiencing a decline following the company's decision to lower its preliminary Q3 revenue guidance.
October 10, 2024 | 7:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Bionano Genomics has reduced its preliminary Q3 revenue guidance, leading to a decrease in its stock price.
The reduction in revenue guidance is a negative indicator for the company's financial performance, likely causing investors to sell off shares, resulting in a stock price decline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100